| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A655812-1ml |
1ml |
期货  |
|
| 别名 | ATX 抑制剂 5 |
|---|---|
| 规格或纯度 | 10mM in DMSO |
| 英文名称 | ATX inhibitor 5 |
| 生化机理 | ATX 抑制剂 5 是一种强效的口服活性自体交联素（ATX）抑制剂，其 IC 50 为 15.3 nM。ATX 抑制剂 5 具有抗肝纤维化的作用，能显著降低 CCl4 诱导的肝纤维化水平。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC 50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently In Vitro ATX inhibitor 5 (compound 10g) (IC 50 s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC). ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: CFs and t-HSC/Cl-6 cells Concentration: 0.0001, 0.01, 1, 100, 10000 µM Incubation Time: 48 hours Result: Displayed activities against CFs and t-HSC/Cl-6 cells with IC 50 s of 1.21 and 0.78 µM, respectively. In Vivo ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Konmin mice (8-week old, 22-25 g) Dosage: 20, 40 mg/kg Administration: Orally; once daily for two weeks Result: Prominently reduced CCl4-induced hepatic fibrosis level. IC50& Target:Autotaxin |
| Isomeric SMILES | C1CN(CC2=C1N=CN=C2NC3=CC=CC(=C3)C(F)(F)F)C(=O)N/N=C/C4=CC=C(C=C4)Cl |
|---|---|
| PubChem CID | 146014477 |
| 分子量 | 474.87 |
首页
400-620-6333
